Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 06 Mar 2023
USA: The syrup drug Diethylene glycol (DEG), a drug commonly used to prevent infections, is the cause of kidney disease...
Read Full NewsModelling shows fewer cases and deaths with screening starting at age 45 years.
A phase 3 trial examines whether carfilzomib-lenalidomide-dexamethasone maintenance therapy improves disease control compared with lenalidomide alone in patients with multiple myeloma.
Although many surgeons avoid it, nipple-sparing mastectomy after radiation is a feasible alternative to skin-sparing mastectomy and may help preserve patients’ psychological well-being.
1.
Routine breast cancer screening can bring better outcomes for patients
2.
Chemotherapy before surgery helps patients with nose and sinus cancer avoid debilitating eye and bone removal
3.
Achieves a High Disease Control Rate in Head and Neck BCC with Vismodegib-RT Regimen.
4.
Talk About Medication Costs, Bringing Back Touch, and Understanding From Dish Tumors.
5.
According to a study, breast cancer cells work together to physically breach barriers and proliferate.
1.
A Closer Look at Poorly Differentiated Carcinoma: Uncovering its Complexities
2.
The Future is Now: Navigating the Precision Revolution in Oncology Treatment
3.
Innovative Bioengineering Approaches for Erectile Function Recovery After Radical Prostatectomy
4.
Leukemia in Focus: Tools, Trials, and Therapy Strategies for Modern Medical Practice
5.
The Predictive Power of Targeted Radionuclide Therapy in Advanced Breast Cancer
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A New Era in Managing Cancer-Associated Thrombosis
2.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
3.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
4.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
5.
Efficient Management of First line ALK-rearranged NSCLC - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge